HARPOON THERAPEUTICS Beats Expectations With -$0.35 Eps

Trending News 🌥️

Harpoon Therapeutics ($NASDAQ:HARP) is a clinical-stage biopharmaceutical company. They focus on the development of novel immuno-oncology therapeutics. Their goal is to improve the lives of patients with cancer. Harpoon Therapeutics released their third quarter GAAP EPS results.

Their EPS was -$0.35. This beat expectations by $0.20. This was driven by higher research and development expenses.

Earnings

HARPOON THERAPEUTICS‘s revenue for the quarter decreased by 3.0% compared to the same quarter last year.

Price History

HARPOON THERAPEUTICS stock opened at $0.8 on Tuesday and closed at $0.8, up by 3.0% from its previous closing price of $0.8. This beats expectations as the company reported a loss of -$0.35 per share. Despite the loss, investors are optimistic about the company’s future prospects as it is working on developing new treatments for cancer and other diseases.

VI Analysis

– Company’s fundamentals reflect its long term potential, below analysis on HARPOON THERAPEUTICS are made simple by VI app. – VI Star Chart shows that HARPOON THERAPEUTICS is strong in growth, medium in asset and weak in dividend, profitability. – HARPOON THERAPEUTICS is classified as ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. – what type of investors may interested in such company. – HARPOON THERAPEUTICS has an intermediate health score of 4/10 with regard to its cashflows and debt, is likely to pay off debt and fund future operations.

VI Peers

The company’s pipeline includes two Phase 1 clinical trials for its lead product, HPN424, and a Phase 2 clinical trial for HPN536. Harpoon’s competitors include BrightPath Biotherapeutics Co Ltd, Talaris Therapeutics Inc, and F-Star Therapeutics Inc.

– BrightPath Biotherapeutics Co Ltd ($TSE:4594)

BrightPath Biotherapeutics Co Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. The company’s lead product candidate is BH-301, a novel immunotherapy that is in clinical development for the treatment of solid tumors. BrightPath Biotherapeutics Co Ltd has a market cap of 7.71B as of 2022, a Return on Equity of -43.51%. The company’s focus on developing innovative therapies for the treatment of cancer makes it a compelling investment opportunity for investors interested in the healthcare sector.

– Talaris Therapeutics Inc ($NASDAQ:TALS)

Talaris Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing a proprietary cell therapy platform to treat patients with autoimmune diseases, inflammatory disorders and blood-based cancers. The Company’s product candidates include T cell receptor (TCR) modified T cells, natural killer (NK) cells, and CAR T cells. Talaris Therapeutics Inc is headquartered in Cambridge, Massachusetts.

– F-star Therapeutics Inc ($NASDAQ:FSTX)

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company, which engages in the research and development of novel antibody therapeutics. Its pipeline includes FS102, FS103, and FS404. The company was founded by Andrew J. Allen, Christoph A. Borner, and James P. Allison in 2016 and is headquartered in Cambridge, MA.

Summary

Harpoon Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies to treat cancer and other serious diseases.